Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016809
Chunk: 23

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 23
---
 to exercise that portion of the warrants that would result in the          
 selling shareholder and its affiliates owning, after exercise, a number of our Ordinary Shares     
 in excess of the beneficial ownership limitation. The amounts and percentages in the table         
 do not give effect to the 9.99% beneficial ownership limitation, if applicable. Iroquois           
 Capital Management L.L.C. is the investment manager of Iroquois Master Fund Ltd. Iroquois          
 Capital Management, LLC has voting control and investment discretion over securities held          
 by Iroquois Master Fund. As Managing Members of Iroquois Capital Management, LLC, Richard          
 Abbe and Kimberly Page make voting and investment decisions on behalf of Iroquois Capital          
 Management, LLC in its capacity as investment manager to Iroquois Master Fund Ltd. As a result     
 of the foregoing, Mr. Abbe and Mrs. Page may be deemed to have beneficial ownership (as determined 
 under Section 13(d) of the Securities Exchange Act of 1934, as amended) of the securities          
 held by Iroquois Capital Management and Iroquois Master Fund. The principal business address       
 of Iroquois Master Fund Ltd. is c/o Iroquois Capital Management, LLC, 2 Overhill Road, Suite       
 400, Scarsdale, NY 10583.                                                                          |

| (11) | The selling shareholder holds Series                                                              
 D Warrants which entitle the selling shareholder to purchase an aggregate of 4,800,000 Ordinary   
 Shares (in the form of Depositary Shares), which we are registering hereby. The warrants          
 are subject to a beneficial ownership limitation of 9.99%, which does not permit the selling      
 shareholder to exercise that portion of the warrants that would result in the selling shareholder 
 and its affiliates owning, after exercise, a number of our Ordinary Shares in excess of the       
 beneficial ownership limitation. The amounts and percentages in the table do not give effect      
 to the 9.99% beneficial ownership limitation, if applicable. The principal business address       
 of Keystone Capital Partners LLC is 139 Fulton Street, Suite 412, New York, NY 10038.             |

| (12) | The selling shareholder holds Series                                                              
 D Warrants which entitle the selling shareholder to purchase an aggregate of 9,600,000 Ordinary   
 Shares (in the form of Depositary Shares), which we are registering hereby. The warrants          
 are subject to a beneficial ownership limitation of 9